Introduction:
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced that its newly upgraded biologics facility in Bangalore, India, will be operational in the second half of 2024. The facility is expected to support the clinical and commercial supply of biologics for U.S. and European clients.
- Syngene’s newly upgraded biologics facility in Bangalore, India, will be operational in the second half of 2024.
- The facility includes two production suites with a total capacity of 20KL, as well as two high-speed vial filling lines capable of producing up to one million vials per day.
- The facility will triple Syngene’s biomanufacturing capacity and will support the company’s core business as well as emerging areas in ADCs and cell and gene therapy.
- Further expansion plans include additional vial filling isolator lines and drug substance expansion into perfusion cell culture processing.
- The facility is integrated with other biologics capabilities in Bangalore, including R&D scientists and other manufacturing facilities.
Conclusion:
Syngene’s newly upgraded biologics facility in India is expected to significantly expand the company’s biomanufacturing capacity and support the growing demand for biologics. The facility will provide clinical and commercial supply services to U.S. and European clients and will also cater to the emerging areas of ADCs and cell and gene therapy. With further expansion plans in the pipeline, Syngene aims to meet the increasing demand for biologics manufacturing and enhance its capabilities in the field.
